敲除芳香烃受体基因对肝细胞癌代谢途径和物质的影响

肝癌电子杂志 ›› 2023, Vol. 10 ›› Issue (4): 23-28.

敲除芳香烃受体基因对肝细胞癌代谢途径和物质的影响

魏哲文¹, 朱青², 蔡建强^1,*

1.国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院肝胆外科,北京 100021;
2.首都医科大学附属北京友谊医院检验科,北京 100050

收稿日期:2023-09-14 出版日期:2023-12-31 发布日期:2024-02-05
通讯作者: ^*蔡建强,E-mail：caijianqiang@cicams.ac.cn
基金资助:
国家自然科学基金青年科学基金（82302892）; 中国医学科学院医学与健康科技创新工程项目（2021-I2M-1-066）

Effect of aryl hydrocarbon receptor gene knockout on metabolic pathways and metabolites in hepatocellular carcinoma

Wei Zhewen¹, Zhu Qing², Cai Jianqiang^1,*

1. Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100021, China;
2. Department of Clinical Laboratory Diagnostics, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

Received:2023-09-14 Online:2023-12-31 Published:2024-02-05
Contact: ^*Cai Jianqiang, E-mail: caijianqiang@cicams.ac.cn

摘要/Abstract

摘要： 目的: 研究敲除芳香烃受体（aryl hydrocarbon receptor,AHR）基因对肝细胞癌（hepatocellular carcinoma,HCC）代谢途径和物质的影响。
方法: 利用成簇规律间隔短回文重复序列（clustered regularly interspaced short palindromic repeats,CRISPR）/Cas9技术构建AHR基因敲除的PLC/PRF/5肝癌细胞系,对野生型（AHR-WT）和AHR基因敲除（AHR-KO）肝癌细胞的代谢物质进行非靶向代谢组学检测,对其代谢物质差异进行分析,使用Metaboanalyst 4.0进行代谢通路富集分析,并寻找差异代谢物质。
结果: 将AHR-WT肝癌细胞和AHR-KO肝癌细胞分别进行正、负离子模式下的代谢物质检测,其前10位的功能富集结果包括氨基酸代谢（谷氨酸代谢、甘氨酸和丝氨酸代谢、精氨酸和脯氨酸代谢、蛋氨酸代谢、天冬氨酸代谢、尿素循环、氨再循环）、能量代谢[谷胱甘肽代谢、沃伯格（Warburg）效应]及核苷酸代谢（嘌呤代谢）。对差异代谢物质进行通路富集分析得到8条与肿瘤作用机制密切相关的代谢通路,包括精氨酸和脯氨酸代谢,精氨酸生物合成,嘧啶代谢,丙氨酸、天冬氨酸和谷氨酸代谢,苯丙氨酸、酪氨酸和色氨酸的生物合成,嘌呤代谢,赖氨酸退化,抗坏血酸和醛酸盐代谢。与AHR-WT肝癌细胞相比,AHR-KO肝癌细胞L-精氨酸、L-苯丙氨酸、L-酪氨酸、尿苷和黄嘌呤明显下调,而还原型烟酰胺腺嘌呤二核苷酸（nicotinamide adenine dinucleotide,NADH）、氧化型谷胱甘肽和还原型烟酰胺腺嘌呤二核苷酸磷酸（nicotinamide adenine dinucleotide phosphate,NADPH）明显上调。
结论: AHR基因在HCC代谢过程中可能发挥重要作用,以AHR基因为靶点的HCC代谢组学变化可能是新的抗肿瘤治疗方案的研究方向。

关键词: 肝细胞癌, 芳香烃受体, 代谢组学

Abstract: Objective:To investigate the effect of aryl hydrocarbon receptor (AHR) gene knockout on metabolic pathways and metabolites in hepatocellular carcinoma (HCC). Method:PLC/PRF/5 hepatoma cell line with AHR knockout was constructed by clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 technology. Untargeted metabolomics was performed on the wild type (AHR-WT) and AHR knockout (AHR-KO) hepatoma cells to detect the metabolites, and the differential metabolites between the two groups were analyzed. Metaboanalyst 4.0 was used to perform metabolic pathway enrichment analysis and find differential metabolites.
Result:The AHR-WT and AHR-KO hepatoma cells were examined for metabolites under positive and negative ionic model respectively. The results showed that the top 10 functional enrichments were mainly amino acid metabolism glutamate metabolism, glycine and serine metabolism, arginine and proline metabolism, methionine metabolism, aspartate metabolism, urea cycle, ammonia recycling, energy metabolism glutathione metabolism, Warburg effect and nucleotide metabolism purine metabolism. The pathway enrichment analysis showed that eight metabolic pathways were found including arginine and proline metabolism, arginine biosynthesis, pyrimidine metabolism, alanine, aspartic acid and glutamate metabolism, phenylalanine, tyrosine and tryptophan biosynthesis, purine metabolism, lysine degradation, ascorbic acid and uronate metabolism. Compared with AHR-WT hepatoma cells, the levels of L-arginine, L-phenylalanine, L-tyrosine, uridine and xanthine were significantly down-regulated in AHR-KO hepatoma cells. Nicotinamide adenine dinucleotide (NADH), oxidized glutathione and nicotinamide adenine dinucleotide phosphate (NADPH) were significantly up-regulated in the AHR-KO cells. Conclusion:AHR may play an important role in the metabolism of HCC, and the research on the metabonomics of HCC by targeting AHR may be a new anti-tumor treatment strategy.

Key words: Hepatocellular carcinoma, Aryl hydrocarbon receptor, Metabolomics

魏哲文, 朱青, 蔡建强. 敲除芳香烃受体基因对肝细胞癌代谢途径和物质的影响[J]. 肝癌电子杂志, 2023, 10(4): 23-28.

Wei Zhewen, Zhu Qing, Cai Jianqiang. Effect of aryl hydrocarbon receptor gene knockout on metabolic pathways and metabolites in hepatocellular carcinoma[J]. Electronic Journal of Liver Tumor, 2023, 10(4): 23-28.

参考文献

[1] SUNG H, FERLAY J, SIEGEL R L, et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版)[J/CD]. 肝癌电子杂志, 2022, 9(1): 1-22.
[3] HANAHAN D.Hallmarks of Cancer: New Dimensions[J]. Cancer Discov, 2022, 12(1): 31-46.
[4] SUNG J Y, CHEONG J H.Pan-Cancer Analysis Reveals Distinct Metabolic Reprogramming in Different Epithelial-Mesenchymal Transition Activity States[J]. Cancers (Basel), 2021, 13(8): 1778.
[5] TANG D, KROEMER G, KANG R. Ferroptosis in hepatocellular carcinoma: from bench to bedside[J]. Hepatology, 2023. Online ahead of print.
[6] LI Q, CHEN K, ZHANG T, et al.Understanding sorafenib-induced ferroptosis and resistance mechanisms: Implications for cancer therapy[J]. Eur J Pharmacol, 2023, 955: 175913.
[7] BOCK K W.Aryl hydrocarbon receptor (AHR): From selected human target genes and crosstalk with transcription factors to multiple AHR functions[J]. Biochem Pharmacol, 2019, 168: 65-70.
[8] ZHU Q, MA Y, LIANG J, et al.AHR mediates the aflatoxin B1 toxicity associated with hepatocellular carcinoma[J]. Signal Transduct Target Ther, 2021, 6(1): 299.
[9] CHEN C T, WU P H, HU C C, et al.Aberrant Upregulation of Indoleamine 2,3-Dioxygenase 1 Promotes Proliferation and Metastasis of Hepatocellular Carcinoma Cells via Coordinated Activation of AhR and beta-Catenin Signaling[J]. Int J Mol Sci, 2021, 22(21): 11661.
[10] WANG Z, CHEN F, WANG Y, et al.Blockade of chemo-resistance to 5-FU by a CK2-targeted combination via attenuating AhR-TLS-promoted genomic instability in human colon cancer cells[J]. Toxicol Appl Pharmacol, 2023, 475: 116647.
[11] LIU Q, HUA S, WANG X, et al.The introduction of immunosuppressor (TDO inhibitor) significantly improved the efficacy of irinotecan in treating hepatocellular carcinoma[J]. Cancer Immunol Immunother, 2021, 70(2): 497-508.
[12] NAVARRO C, ORTEGA A, SANTELIZ R, et al.Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches[J]. Pharmaceutics, 2022, 14(6): 1303.
[13] LI X, RAMADORI P, PFISTER D, et al.The immunological and metabolic landscape in primary and metastatic liver cancer[J]. Nat Rev Cancer, 2021, 21(9): 541-557.
[14] AJOOLABADY A, TANG D, KROEMER G, et al.Ferroptosis in hepatocellular carcinoma: mechanisms and targeted therapy[J]. Br J Cancer, 2023, 128(2): 190-205.
[15] ZHENG J, CONRAD M.The Metabolic Underpinnings of Ferroptosis[J]. Cell Metab, 2020, 32(6): 920-937.
[16] MISSIAEN R, ANDERSON N M, KIM L C, et al. GCN2 inhibition sensitizes arginine-deprived hepatocellular carcinoma cells to senolytic treatment[J]. Cell Metab, 2022, 34(8): 1151-1167.e7.
[17] ABOU-ALFA G K, QIN S, RYOO B Y, et al. Phase Ⅲ randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma[J]. Ann Oncol, 2018, 29(6): 1402-1408.
[18] MURRAY I A, PATTERSON A D, PERDEW G H.Aryl hydrocarbon receptor ligands in cancer: friend and foe[J]. Nat Rev Cancer, 2014, 14(12): 801-814.
[19] YANG F, LI J, DENG H, et al.GSTZ1-1 Deficiency Activates NRF2/IGF1R Axis in HCC via Accumulation of Oncometabolite Succinylacetone[J]. EMBO J, 2019, 38(15): e101964.
[20] HUANG G, XIE S, WANG M, et al.Metabolite profiling analysis of hepatitis B virus-induced liver cirrhosis patients with minimal hepatic encephalopathy using gas chromatography-time-of-flight mass spectrometry and ultra-performance liquid chromatography-quadrupole-time-of-flight mass spectrometry[J]. Biomed Chromatogr, 2023, 37(1): e5529.
[21] MULLEN N J, SINGH P K.Nucleotide metabolism: a pan-cancer metabolic dependency[J]. Nat Rev Cancer, 2023, 23(5): 275-294.